← Back to Search

Dietary Supplement

Salmon Peptide Supplement for Metabolic Syndrome (SPF1 Trial)

N/A
Waitlist Available
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet at least one of the following criteria: Plasma TG > 1.35 mmol/L, Fasting glycemia ≥ 5.6 mmol/L and ≤ 6.9 mmol/L, HbA1c ≥ 5.7% and ≤ 6.4%, Insulin concentration > 42 pmol/L
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change between the beginning and th end of the intervention (6 weeks)
Awards & highlights

SPF1 Trial Summary

This trial will test the safety and effects of two doses of salmon peptide fraction on metabolic syndrome risk factors in overweight-obese men and women.

Who is the study for?
This trial is for overweight-obese men and women with a waist size of at least 94 cm for men or 80 cm for women. They must have certain metabolic syndrome risk factors like high triglycerides, blood sugar, HbA1c, or insulin levels but can't be on any related medications. No recent weight loss, surgery, or use of supplements affecting metabolism is allowed.Check my eligibility
What is being tested?
The study tests the safety and effects on cardiometabolic health of two doses (7.5g and 15g) of salmon peptide fraction in participants with metabolic syndrome. It uses advanced biological analysis to understand how these supplements might work.See study design
What are the potential side effects?
While specific side effects are not listed here, potential risks may include allergic reactions due to fish/seafood ingredients in the supplement or gastrointestinal discomfort as commonly seen with dietary supplements.

SPF1 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My blood tests show high triglycerides, blood sugar, HbA1c, or insulin levels.

SPF1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change between the beginning and th end of the intervention (6 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change between the beginning and th end of the intervention (6 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse event and general acceptability evaluated by questionnaires
Change in complete blood count using blood sampling
Change in hepatic enzymes using blood sampling
+1 more
Secondary outcome measures
Change in blood pressure
Change in body mass index
Change in glucose metabolism
+3 more

SPF1 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SPFExperimental Treatment2 Interventions
Salmon peptide fraction supplement: powder mixed in water
Group II: ComparatorActive Control2 Interventions
Casein peptide fraction supplement: powder mixed in water

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
417 Previous Clinical Trials
172,219 Total Patients Enrolled
26 Trials studying Metabolic Syndrome
1,982 Patients Enrolled for Metabolic Syndrome

Media Library

Salmon Peptide Fraction (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05025462 — N/A
Metabolic Syndrome Research Study Groups: Comparator, SPF
Metabolic Syndrome Clinical Trial 2023: Salmon Peptide Fraction Highlights & Side Effects. Trial Name: NCT05025462 — N/A
Salmon Peptide Fraction (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05025462 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the core purpose of this trial?

"The main outcome to be assessed over the 6-week experiment is a transformation in complete blood count through blood sampling. Additional secondary objectives encompass shifts in systolic and diastolic arterial pressure as an indication of metabolic syndrome risk, alteration in insulin secretion measured by C-peptide concentration during a 3 hour oral glucose tolerance test, and lastly fluctuations in body mass index via weight and height measurements also reflecting metabolic risk factors."

Answered by AI

Is enrolment in this research study ongoing?

"Affirmative. The information shared on clinicaltrials.gov suggests that the trial is still in search of participants; it was first announced on November 1st 2021 and its most recent modification happened October 3rd 2022. This research project seeks to recruit 40 volunteers from a single site."

Answered by AI

How many individuals are taking part in this investigation?

"Affirmative, the information on clinicaltrials.gov supports that this research is still in its recruitment phase. The study initially appeared on November 1st 2021 with improvements made as recently as October 3rd 2022 and requires 40 volunteers from a single site."

Answered by AI

Is eligibility for this trial still available?

"To join this medical trial, individuals must have metabolic syndrome and be between 18 to 75 years old. Approximately 40 volunteers are being accepted."

Answered by AI

Is this research endeavor accommodating participants over 40 years of age?

"This research study is recruiting volunteers who are aged 18 or over, yet under 75."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Salmon Peptide Fraction: Safety and Cardiometabolic Health
André Marette 2021. "Salmon Peptide Fraction: Safety and Cardiometabolic Health". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05025462.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top